Discovery of MOTS-c as a Mitochondrial-Derived Peptide Regulating Metabolic Homeostasis
The landmark 2015 study by Lee et al. identified MOTS-c as a novel short open reading frame (sORF) encoded within the mitochondrial 12S rRNA gene. Researchers demonstrated that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The peptide’s primary target organ was identified as skeletal muscle, where it inhibits the folate cycle and its tethered de novo purine biosynthesis pathway, leading to activation of AMPK. This discovery established MOTS-c as the first mitochondrial-encoded peptide shown to actively regulate metabolic homeostasis at both the cellular and organismal level.
Citation: Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. PubMed PMID: 25738459
MOTS-c as a Regulator of Plasma Metabolites and Insulin Sensitivity in Obese Models
Kim et al. (2019) used an unbiased metabolomics approach to examine the effect of MOTS-c on plasma markers of metabolic dysfunction in diet-induced obese (DIO) mice. The study found that MOTS-c injection reduced three key metabolic pathways — sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism — all of which are typically upregulated in obese and type 2 diabetes models. The data demonstrated that MOTS-c improves insulin sensitivity and increases beta-oxidation to prevent fat accumulation, providing a mechanistic understanding of how the peptide reduces body weight and ameliorates fatty liver in DIO mice.
Citation: Kim SJ, Miller B, Kumagai H, Silverstein AR, Flores M, Cohen P. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity. Physiol Rep. 2019;7(13):e14171. doi:10.14814/phy2.14171. PubMed PMID: 31293078
MOTS-c: A Novel Mitochondrial-Derived Peptide Regulating Muscle and Fat Metabolism
This comprehensive review by Lee et al. (2016) characterized MOTS-c as a mitochondrial-derived peptide hormone with broad metabolic implications. The authors detailed how MOTS-c targets skeletal muscle and enhances glucose metabolism, with implications for the regulation of obesity, diabetes, exercise physiology, and longevity. The review positioned MOTS-c within the broader framework of mitochondrial-derived peptides (MDPs) alongside humanin, establishing the concept that mitochondria function not merely as metabolic organelles but as active signaling units that encode hormone-like peptides capable of regulating metabolism within and between cells.
Citation: Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182-187. doi:10.1016/j.freeradbiomed.2016.05.015. PubMed PMID: 27216708
MOTS-c Nuclear Translocation and Gene Expression Regulation Under Metabolic Stress
Kim et al. (2018) made the groundbreaking discovery that MOTS-c, a peptide encoded in the mitochondrial genome, translocates to the nucleus and regulates nuclear gene expression following metabolic stress. This nuclear translocation occurs in an AMPK-dependent manner. In the nucleus, MOTS-c regulated a broad range of genes in response to glucose restriction, including those with antioxidant response elements (ARE), and interacted with ARE-regulating stress-responsive transcription factors such as NFE2L2/NRF2. These findings indicate that the mitochondrial and nuclear genomes co-evolved to independently encode factors that cross-regulate each other, representing a paradigm shift in understanding mito-nuclear communication.
Citation: Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516-524.e7. doi:10.1016/j.cmet.2018.06.008. PubMed PMID: 29983246
MOTS-c as an Exercise-Induced Regulator of Age-Dependent Physical Decline
Lai et al. (2021) provided evidence that MOTS-c functions as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. The study demonstrated that late-life initiated intermittent MOTS-c treatment (3x/week, beginning at 23.5 months of age) increased physical capacity and healthspan in aged mice. Critically, the researchers showed that in humans, exercise induces endogenous MOTS-c expression in both skeletal muscle (11.9-fold increase) and in circulation (1.5-fold increase). These findings established MOTS-c as a mitochondrial-encoded exercise factor and a potential target for age-related physical decline.
Citation: Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. doi:10.1038/s41467-020-20790-0. PubMed PMID: 33473109
Limitations and Current Knowledge Gaps
The research summarized on this page reflects findings from preclinical models (primarily rodent and in vitro studies). Several important limitations should be acknowledged when evaluating this evidence:
- Lack of human clinical trials: No large-scale, randomized controlled trials in humans have been completed for most research peptides, including MOTS-C — Published Research. Animal data does not directly translate to human outcomes.
- Dosing uncertainty: There are no standardized, clinically validated dosing protocols. Doses used in animal studies may not be relevant to human applications.
- Unknown long-term safety profile: Long-term toxicity, chronic administration effects, and potential off-target biological interactions remain unstudied.
- Regulatory status: MOTS-C — Published Research is not approved by the FDA or other major regulatory agencies for human therapeutic use. Regulatory classification varies by jurisdiction.
- Publication bias: Positive results are more likely to be published than negative findings, which may inflate the apparent strength of evidence.
Researchers should evaluate these findings in context and avoid extrapolating preclinical results to clinical recommendations.
Reviewed for scientific accuracy — Chameleon Peptides Research Team. Last reviewed: March 2026.